X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Capital Expenditures came in at $41000.0 in Q4 2024, down 55.43% on a QoQ basis from $92000.0 in Q3 2024.
X4 Pharmaceuticals (XFOR) Capital Expenditures (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 8 years of Capital Expenditures data on file, last reported at $41000.0 in Q4 2024.
- Quarterly Capital Expenditures changed N/A year-over-year to $41000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $41000.0 (down 85.61% YoY) and the FY2024 annual result came in at $326000.0, changed N/A from the prior year.
- Capital Expenditures fell to $41000.0 in Q4 2024, from $92000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q3 2020 to a low of -$690000.0 in Q4 2020.
- A 5-year average of $133666.7 and a median of $36000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures jumped 1737.04% — and 2021, when it sank 5611.11%.
- Tracing XFOR's Capital Expenditures over 5 years: stood at -$690000.0 in 2020, then surged by 101.88% to $13000.0 in 2021, then soared by 161.54% to $34000.0 in 2022, then slumped by 126.47% to -$9000.0 in 2023, then soared by 555.56% to $41000.0 in 2024.
- The last three Capital Expenditures figures came in at $41000.0 (Q4 2024), $92000.0 (Q3 2024), and $134000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 38,000.00 |
| Jun 30, 2022 | 38,000.00 |